Disease relevance of Cetraxate

• The several trans-GMCHA arylamide derivatives showed more potent inhibitory effects on the stress- and HCl-ethanol-induced gastric ulcers than cetraxate in rats [1].
• Influence of Helicobacter pylori infection and cetraxate on gastric mucosal blood flow during healing of endoscopic mucosal resection-induced ulcers [2].
• AIM: To determine the efficacy and safety of DA-9601 on erosive gastritis versus cetraxate as a standard drug by gastrointestinal endoscopy [3].
• Histological analysis also confirmed that cetraxate effectively prevented deep mucosal necrosis, but showed that it was without protective effect on the surface epithelial disruption and submucosal edema in response to HCl.ethanol [4].
• Cetraxate is not superior to placebo in the treatment of duodenal ulcer [5].

High impact information on Cetraxate

• Oxyradical generation from leukocytes during endotoxin-induced microcirculatory disturbance in rat mesentery--attenuating effect of cetraxate [6].
• Cetraxate plus LAC for 1 week is a safe and effective regime for the eradication of H. pylori in patients after partial gastrectomy [7].
• Single administration of cetraxate caused significant increases in plasma CGRP concentration at 60-120 min compared with placebo [8].
• Enzymatic preparation of D-beta-acetylthioisobutyric acid and cetraxate hydrochloride using a stereo- and/or regioselective hydrolase, 3,4-dihydrocoumarin hydrolase from Acinetobacter calcoaceticus [9].
• The products of these reactions were identified as D-beta-acetylthioisobutyrate and cetraxate, respectively, i.e., the hydrolysis reactions catalyzed by DCH were stereo- and/or regioselective [9].

Chemical compound and disease context of Cetraxate

• Comparative study of cimetidine and cetraxate in the treatment of peptic ulcer [10].
• Forty-nine Chinese patients, ages 65 years or over, with endoscopically and pathologically diagnosed benign gastric ulcer, completed a randomized double-blind double dummy trial in treatment with either cetraxate 200 mg four times daily or ranitidine 150 mg two times daily for 12 weeks or less if the gastric ulcer had completely healed [11].
• The no change and aggravating rates were also lower for redness in the 1st week (p less than 0.05) and edema in the 1st week (p less than 0.10) in the cetraxate group than in the aldioxa group [12].

Biological context of Cetraxate

• Topical administration of cetraxate (200 mg in 10 ml saline) prevented the increase in mucosal blood volume and decrease in mucosal hemoglobin oxygenation which had been induced by ethanol loading in the stomach [13].
• These experimental results suggest that the antiulcer effect of cetraxate is due to the improvement of blood circulation in the gastric mucosa [14].

Anatomical context of Cetraxate

• In conclusion, cetraxate showed a protective effect on mucosal microcirculation that resulted in the maintenance of the gastric mucosal integrity against ethanol loading in the gastric mucosa [13].
• BACKGROUND AND AIM: Helicobacter pylori (H. pylori) infection is known to affect the gastric microcirculation, and cetraxate is reported to accelerate gastric ulcer healing, possibly by augmenting gastric mucosal blood flow (MBF) [2].
• These findings suggest that cetraxate may prevent the connective tissue in the ulcer location from decomposition due to lysosomal enzymes such as beta-glucuronidase, thereby accelerating the recovery from ulcer [15].

Associations of Cetraxate with other chemical compounds

• The efficacy of two anti-ulcer drugs, Cimetidine and Cetraxate, on the mucus glycoproteins of gastric mucosa in the aspirin-induced gastric damage was studied in rats [16].
• Carbenoxolone and cetraxate given orally protected the gastric mucosa against 0.6N HCl [17].

Gene context of Cetraxate

• Endothelin-1-induced gastric ulcer is attenuated by cetraxate [18].

Analytical, diagnostic and therapeutic context of Cetraxate

• Efficacy of triple therapy plus cetraxate for the Helicobacter pylori eradication in partial gastrectomy patients [7].
• Rats were divided into two groups: the control group and the cetraxate group [19].
• We investigated the effect of the anti-ulcer drug cetraxate on the development of the gastric ulcer induced by the submucosal injection of endothelin-1 in the rat gastric body, and its effects on gastric mucosal hemodynamics and tissue oxygenation by Laser doppler flowmetry and tissue spectrophotometry [18].
• Simultaneous or previous oral administration of Cimetidine or Cetraxate with aspirin reduced the diminution of the mucus glycoproteins which was occurred by aspirin administration [16].
• Therapeutic effects of cetraxate against acute gastritis and acute aggravation of chronic gastritis. Endoscopic investigation by the double-blind method [12].

References